MétaCan
Menu
Back to cohort
Record W4280488168 · doi:10.1136/jitc-2021-003487

Time 2EVOLVE: predicting efficacy of engineered T-cells – how far is the bench from the bedside?

2022· review· en· W4280488168 on OpenAlexaff
Sònia Guedan, Maik Luu, Delphine Ammar, Paula Barbao, Chiara Bonini, Philippe Bousso, Christian J. Buchholz, Monica Casucci, Biagio De Angelis, Emmanuel Donnadieu, David Espie, Béatrice Gréco, Richard W.J. Groen, Johannes B. Huppa, Chahrazade Kantari‐Mimoun, Bruno Laugel, Mary Mantock, Janet L. Markman, Emma Morris, Concetta Quintarelli, Michael Rade, Kristin Reiche, Alba Rodríguez-García, Juan R. Rodríguez-Madoz, Eliana Ruggiero, Maria Themeli, Michael Hudecek, Ibtissam Marchiq

Bibliographic record

VenueJournal for ImmunoTherapy of Cancer · 2022
Typereview
Languageen
FieldMedicine
TopicCAR-T cell therapy research
Canadian institutionsInstitute of Infection and Immunity
FundersInnovative Medicines InitiativeEuropean CommissionEuropean Federation of Pharmaceutical Industries and Associations
KeywordsT-cell receptorCancer immunotherapyMedicineImmunotherapyTranslational researchChimeric antigen receptorT cellCancer researchImmune systemComputational biologyImmunologyBioinformaticsBiologyPathology

Abstract

fetched live from OpenAlex

Immunotherapy with gene engineered CAR and TCR transgenic T-cells is a transformative treatment in cancer medicine. There is a rich pipeline with target antigens and sophisticated technologies that will enable establishing this novel treatment not only in rare hematological malignancies, but also in common solid tumors. The T2EVOLVE consortium is a public private partnership directed at accelerating the preclinical development of and increasing access to engineered T-cell immunotherapies for cancer patients. A key ambition in T2EVOLVE is to assess the currently available preclinical models for evaluating safety and efficacy of engineered T cell therapy and developing new models and test parameters with higher predictive value for clinical safety and efficacy in order to improve and accelerate the selection of lead T-cell products for clinical translation. Here, we review existing and emerging preclinical models that permit assessing CAR and TCR signaling and antigen binding, the access and function of engineered T-cells to primary and metastatic tumor ligands, as well as the impact of endogenous factors such as the host immune system and microbiome. Collectively, this review article presents a perspective on an accelerated translational development path that is based on innovative standardized preclinical test systems for CAR and TCR transgenic T-cell products.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow), Insufficient payload (model declined to judge)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.968
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0020.000
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0020.003
Bibliometrics0.0000.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0010.000
Research integrity0.0000.002
Insufficient payload (model declined to judge)0.0190.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.054
GPT teacher head0.376
Teacher spread0.322 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designNot applicable
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations34
Published2022
Admission routes1
Has abstractyes

Explore more

Same venueJournal for ImmunoTherapy of CancerSame topicCAR-T cell therapy researchFrench-language works237,207